Scarica l'app Stockscreener
25.31
8.72%
2.03
Dopo l'orario di chiusura:
25.25
-0.06
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$23.28
Aprire:
$23.36
Volume 24 ore:
3.51M
Relative Volume:
2.38
Capitalizzazione di mercato:
$1.65B
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-11.30
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
+61.42%
1M Prestazione:
+41.79%
6M Prestazione:
+400.20%
1 anno Prestazione:
+322.54%
Intervallo 1D:
$22.77
$25.77
Intervallo di 1 settimana:
$13.69
$25.77
Portata 52W:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
25.31 | 1.52B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - ulpravda.ru
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim - MarketBeat
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
Monte Rosa Therapeutics Reaches Analyst Target Price - Nasdaq
Monte Rosa Therapeutics dips after $200 mln equity offering launched - TradingView — Track All Markets
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Strong-Buy - MarketBeat
Monte Rosa Therapeutics launches $200 million public offering By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics launches $200M public equity offering - MSN
Monte Rosa Therapeutics (GLUE) upgraded to strong buy: Here's why - MSN
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Monte Rosa Therapeutics Ends Current ATM Equity Program - TipRanks
Monte Rosa Therapeutics launches $200 million public offering - Investing.com
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech working on new medicines moves to raise $200M - Stock Titan
Monte Rosa Therapeutics (GLUE) Soars on Promising Inflammation Drug Data - RagingBull
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why - sharewise.com
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush - TipRanks
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
GLUE: MRT-8102 achieved robust hsCRP and fibrinogen reductions with favorable safety in phase I - TradingView — Track All Markets
Why Is Monte Rosa Therapeutics Stock Skyrocketing Wednesday?Monte Rosa Therapeutics (NASDAQ:GLUE) - Benzinga
Monte Rosa Therapeutics: Early MRT-8102 hsCRP Data Underscore Differentiated NLRP3 Opportunity and Attractive Risk-Reward Supporting Buy Rating - TipRanks
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Monte Rosa Therapeutics stock hits 52-week high at $21.89 - Investing.com
Monte Rosa Therapeutics Shares Phase 1 MRT-8102 Data Showing 85% hsCRP Drop, No Safety Flags - MarketBeat
GLUE Hits New High On Positive Phase 1 Data For MRT-8102 In Cardiovascular Risk Participants - RTTNews
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today - TipRanks
Monte Rosa’s MRT-8102 shows promising results in reducing inflammation By Investing.com - Investing.com Nigeria
Why Did GLUE Stock Surge Over 50% In Premarket Today? - Stocktwits
Did Monte Rosa’s Interim MRT-8102 Data Reveal a Turning Point for Its Molecular Glue Platform (GLUE)? - simplywall.st
Monte Rosa reports positive Phase 1 data for MRT-8102 - TipRanks
Monte Rosa’s MRT-8102 shows promising results in reducing inflammation - Investing.com India
Monte Rosa Therapeutics Reports Positive Interim Data from Phase 1 Study of MRT-8102 in Reducing Inflammation in Cardiovascular Disease Risk Patients - Quiver Quantitative
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 - TradingView — Track All Markets
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - The Manila Times
Monte Rosa Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire
Monte Rosa (GLUE) Stock Pre-Market (+8.7%): Positive Phase 1 Data for MRT-8102 - Trefis
Stocks to Watch: Mobileye Global, AAR, Monte Rosa Therapeutics - 富途牛牛
Monte Rosa to present interim results for NEK7-directed MGD By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - The Manila Times
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):